Skip to search formSkip to main contentSkip to account menu

GSK573719

National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Quinuclidines

Narrower (1)

umeclidinium

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD).
BACKGROUND Three classes of inhaler medications are used to manage chronic obstructive pulmonary disease (COPD): long-acting beta… 
2012
2012
Umeclidinium (GSK573719) dose response and dosing interval in COPD
Introduction: Dose differentiation is important in selecting COPD treatments. Objective: Characterize umeclidinium (UMEC), a long… 
2012
2012
Safety, Tolerability And Pharmacokinetics (PK) Of Single And Repeat Doses Of GSK573719 In Healthy Japanese Subjects
2012
2012
Evaluation Of The Effect Of Verapamil, An Inhibitor Of P-Glycoprotein And CYP3A4, On Systemic Exposure And Safety Profile Of GSK573719, A New Long-Acting Muscarinic Antagonist, And Vilanterol, An…
2011
2011
Safety, tolerability and pharmacokinetics (PK) of repeated doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in healthy adults
Introduction: GSK573719 is a new long-acting muscarinic antagonist offering sustained 24-hour bronchodilation in development for… 
2011
2011
The pre-clinical pharmacology of the inhaled muscarinic antagonist GSK573719 predicts once-daily clinical dosing
Introduction: GSK573719 is a new, long-acting muscarinic antagonist offering sustained 24-h bronchodilation currently in phase… 
2011
2011
Safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of GSK573719 inhalation powder in healthy subjects
Introduction: GSK573719 is a new long-acting muscarinic antagonist offering sustained 24-hour bronchodilation in development for… 
2011
2011
Phase II study of once-daily GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD)
Introduction: GSK573719 is a new long-acting muscarinic antagonist offering sustained 24-hour bronchodilation in development for… 
2011
2011
Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of single doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist (LAMA), in patients with COPD
Introduction: GSK573719 is a new LAMA offering sustained 24-hour bronchodilation in development for the treatment of COPD… 
2011
2011
Dose-Related Efficacy of GSK573719: A Long-Acting Muscarinic Receptor Antagonist (LAMA) With Sustained 24-Hour Activity in COPD
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)